NeuroVive and Yungjin Pharm Start Clinical Development in Genetic Mitochondrial Disease
NeuroVive Pharmaceutical AB and Yungjin Pharm Corporation Ltd announced that the clinical phase I study of KL1333 has started in Korea and that the first healthy volunteer has been…
Read More...
Read More...